TY - JOUR
T1 - N-acetyl serotonin derivatives as potent neuroprotectants for retinas
AU - Shen, Jianying
AU - Ghai, Kanika
AU - Sompol, Pradoldej
AU - Liu, Xia
AU - Cao, Xuebing
AU - Iuvone, P. Michael
AU - Ye, Keqiang
PY - 2012/2/28
Y1 - 2012/2/28
N2 - N-acetylserotonin (NAS) is synthesized from serotonin by arylalkylamine N-acetyltransferase (AANAT), which is predominantly expressed in the pineal gland and retina. NAS activates TrkB in a circadian manner and exhibits antidepressant effects in a TrkB-dependent manner. It also enhances neurogenesis in hippocampus in sleep-deprived mice. Here we report the identification of NAS derivatives that possess much more robust neurotrophic effects with improved pharmacokinetic profiles. The compound N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-2- oxopiperidine-3-carboxamide (HIOC) selectively activates TrkB receptor with greater potency than NAS. It potently protects retinas from light-induced retinal degeneration (LIRD),which is tightly coupled with pronounced TrkB activation in retinas. Pharmacokinetic studies demonstrate that this compound is stable in serum and liver microsomes. It can pass the blood-brain barrier and blood-retinal barrier. Hence, HIOC is a good lead compound for further drug development for treating retinal degenerative diseases.
AB - N-acetylserotonin (NAS) is synthesized from serotonin by arylalkylamine N-acetyltransferase (AANAT), which is predominantly expressed in the pineal gland and retina. NAS activates TrkB in a circadian manner and exhibits antidepressant effects in a TrkB-dependent manner. It also enhances neurogenesis in hippocampus in sleep-deprived mice. Here we report the identification of NAS derivatives that possess much more robust neurotrophic effects with improved pharmacokinetic profiles. The compound N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-2- oxopiperidine-3-carboxamide (HIOC) selectively activates TrkB receptor with greater potency than NAS. It potently protects retinas from light-induced retinal degeneration (LIRD),which is tightly coupled with pronounced TrkB activation in retinas. Pharmacokinetic studies demonstrate that this compound is stable in serum and liver microsomes. It can pass the blood-brain barrier and blood-retinal barrier. Hence, HIOC is a good lead compound for further drug development for treating retinal degenerative diseases.
KW - Circadian rhythm
KW - Melatonin
KW - Neurotrophins
KW - Small molecule
UR - http://www.scopus.com/inward/record.url?scp=84863261062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863261062&partnerID=8YFLogxK
U2 - 10.1073/pnas.1119201109
DO - 10.1073/pnas.1119201109
M3 - Article
C2 - 22331903
AN - SCOPUS:84863261062
SN - 0027-8424
VL - 109
SP - 3540
EP - 3545
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 9
ER -